Sleep Medicine Reviews
Volume 8, Issue 5 , Pages 333-338 , October 2004

An update on the pharmacotherapy of excessive daytime sleepiness and cataplexy

References 

  1. Banerjee D, Vitiello MV, Grunstein RR. Pharmacotherapy for excessive daytime sleepiness. Sleep Med Rev. 2004; 8: 339–354
  2. Broughton R, Mamelak M. The treatment of narcolepsy–cataplexy with nocturnal gamma-hydroxybutyrate. Can J Neurol Sci. 1979;6:1–6
  3. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol. 1997;52:27–78
  4. Akimoto H, Honda Y, Takahashi Y. Pharmacotherapy in narcolepsy. Dis Nerv Syst. 1960;21:704–706
  5. Wyatt RJ, Fram DH, Buchbinder R, et al.  Treatment of intractable narcolepsy with a monoamine oxidase inhibitor. N Engl J Med. 1971;285:987–991
  6. Guilleminault C, Mancuso J, Salva MA, et al.  Viloxazine hydrochloride in narcolepsy: a preliminary report. Sleep. 1986;9:275–279
  7. Martinez-Rodriguez J, Iranzo A, Santamaria J, et al.  Status cataplecticus induced by abrupt withdrawal of clomipramine. Neurologia. 2002;17:113–116
  8. Nishino S, Arrigoni J, Shelton J, et al.  Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep. 1993;16:706–712
  9. Tatsumi M, Groshan K, Blakely RD, et al.  Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340:249–258
  10. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994;114:559–565
  11. Mignot E, Renaud A, Nishino S, et al.  Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology (Berl). 1993;113:76–82
  12. Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol. 1999;19:467–489
  13. Hishikawa Y, Ida H, Nakai K, et al.  Treatment of narcolepsy with imipramine (tofranil) and desmethylimipramine (pertofran). J Neurol Sci. 1966;3:453–461
  14. Schmidt HS, Clark RW, Hyman PR. Protriptyline: an effective agent in the treatment of the narcolepsy–cataplexy syndrome and hypersomnia. Am J Psychiatry. 1977;134:183–185
  15. Koch S, Hemrick-Luecke SK, Thompson LK, et al.  Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology. 2003;45:935–944
  16. Kennedy SH, Eisfeld BS, Dickens SE, et al.  Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry. 2000;61:276–281
  17. Larrosa O, de la Llave Y, Bario S, et al.  Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep. 2001;24:282–285
  18. Simpson D, Plosker GL. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs. 2004;64:205–222
  19. Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol. 1993;33:639–677
  20. McCann UD, Ricaurte GA. Amphetamine neurotoxicity: accomplishments and remaining challenges. Neurosci Biobehav Rev. 2004;27:821–826
  21. Wong YN, Simcoe D, Hartman LN, et al.  A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol. 1999;39:30–40
  22. Mignot E, Nishino S, Guilleminault C, et al.  Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep. 1994;17:436–437
  23. Nishino S, Mao J, Sampathkumaran R, et al.  Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online. 1998;1:49–61
  24. Wisor JP, Nishino S, Sora I, et al.  Dopaminergic role in stimulant-induced wakefulness. J Neurosci. 2001;21:1787–1794
  25. Robertson P, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet. 2003;42:123–137
  26. DeBattista C, Doghramji K, Menza MA, et al.  Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64:1057–1064
  27. Happe S. Excessive daytime sleepiness and sleep disturbances in patients with neurological diseases: epidemiology and management. Drugs. 2003;63:2725–2737
  28. Pack AI. Should a pharmaceutical be approved for the broad indication of excessive sleepiness?. Am J Respir Crit Care Med. 2003;167:109–111
  29. Houghton WC, Scammell TE, Thorpy M. Pharmacotherapy for cataplexy. Sleep Med Rev. 2004; 8:355–366
  30. Wong CG, Gibson KM, Snead OC. From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid. Trends Pharmacol Sci. 2004;25:29–34
  31. Mamelak M, Escriu JM, Stokan O. The effects of gamma-hydroxybutyrate on sleep. Biol Psychiatry. 1977;12:273–288
  32. Van Cauter E, Plat L, Scharf MB, et al.  Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young Men. J Clin Invest. 1997;100:745–753
  33. Mignot E, Chen W, Black J. On the value of measuring CSF hypocretin-1 in diagnosing narcolepsy. Sleep. 2003;26:646–649
  34. Lecendreux M, Maret S, Bassetti C, et al.  Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res. 2003;12:347–348
  35. Hecht M, Lin L, Kushida CA, et al.  Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy. Sleep. 2003;26:809–810

PII: S1087-0792(04)00059-0

doi: 10.1016/j.smrv.2004.06.003

Sleep Medicine Reviews
Volume 8, Issue 5 , Pages 333-338 , October 2004

Article Tools